预约演示
更新于：2025-04-16
Gadobutrol
钆布醇
更新于：2025-04-16
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 澳大利亚 (1998-12-02), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H31GdN4O9 |
InChIKeyZPDFIIGFYAHNSK-ZCTZICQLSA-K |
CAS号770691-21-9 |
关联
73
项与 钆布醇 相关的临床试验NCT06854458
The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States (SPINS2) Study
NCT05915728
A Multicenter, Randomized, Prospective Double-blind, Cross-over Phase 3 Study to Evaluate the Efficacy and Safety of 0.04 mmol Gd/kg Body Weight of Gadoquatrane for MRI in Adults With Known or Suspected Pathology of Any Body Region (Except CNS), Compared to 0.1 mmol Gd/kg Approved Macrocyclic Gadolinium-based Contrast Agents (GBCAs)
NCT05915702
A Multicenter, Randomized, Prospective Double-blind, Cross-over Phase 3 Study to Evaluate the Efficacy and Safety of 0.04 mmol Gd/kg Body Weight of Gadoquatrane for MRI in Adults With Known or Suspected Pathology of the Central Nervous System (CNS), Compared to 0.1 mmol Gd/kg Approved Macrocyclic Gadolinium-based Contrast Agents (GBCAs)
100 项与 钆布醇 相关的临床结果
登录后查看更多信息
100 项与 钆布醇 相关的转化医学
登录后查看更多信息
100 项与 钆布醇 相关的专利（医药）
登录后查看更多信息
661
项与 钆布醇 相关的文献（医药）2025-04-01CLINICAL IMAGING
A review of gadolinium-based contrast agents in the setting of repeated MRI for high risk breast cancer screening
Review
作者: Reichman, Melissa ; Foshag, Kelcie ; Prince, Martin ; Tsiouris, Apostolos John
Women who are considered high risk for breast cancer are recommended to undergo supplemental breast cancer screening annually with MRI. There are primarily three safety concerns associated with gadolinium-based contrast agents which include allergic reactions, nephrogenic systemic fibrosis and gadolinium deposition. In this review, we discuss how these risks are affected by molecular structure, will specifically review the difference between the two commonly used agents, gadobutrol and gadoterate, and discuss the most recent FDA approved contrast agent on the market, gadopiclenol.
2025-03-01STROKE
Impact of Subarachnoid Hemorrhage on Human Glymphatic Function: A Time-Evolution Magnetic Resonance Imaging Study
Article
作者: Valnes, Lars Magnus ; Nedregaard, Bård ; Pripp, Are ; Ringstad, Geir ; Sletteberg, Ruth ; Sorteberg, Angelika G. ; Lashkarivand, Aslan ; Eide, Per Kristian ; Rønning, Pål Andre ; Undseth, Ragnhild Marie
BACKGROUND::
Subarachnoid hemorrhage (SAH) is associated with significant mortality and morbidity. The impact of SAH on human glymphatic function remains unknown.
METHODS::
This prospective, controlled study investigated whether human glymphatic function is altered after SAH, how it differs over time, and possible underlying mechanisms. Glymphatic enrichment was examined by intrathecal contrast-enhanced magnetic resonance imaging (MRI, glymphatic MRI), utilizing the MRI contrast agent gadobutrol (Gadovist, Bayer AG, GE; 0.50 mmol) as a cerebrospinal fluid (CSF) tracer. The distribution of the tracer in the brain and the subarachnoid and ventricular CSF spaces was assessed using standardized multi-phase MRI T1 sequences, and between-group differences in percentage change of standardized T1 signal unit ratios over time were analyzed by linear mixed models.
RESULTS::
The study comprised 27 patients with SAH (19 female/8 male; 59.3±10.2 years) who were examined <3 months (n=5), 3 to 6 months (n=10), 6 to 12 months (n=5), or >12 months (n=7) after bleed. A sex- and age-matched control group of 22 individuals (15 female/7 male; 55.5±10.5 years) underwent the same glymphatic MRI protocol but had no neurological or CSF disease. The patients with SAH showed a marked impairment of glymphatic enrichment throughout the brain (particularly addressing the cerebral cortex and subcortical white matter), especially after 24 hours. The glymphatic impairment was accompanied by redistribution of CSF tracer from subarachnoid spaces toward ventricles. These alterations were most pronounced after 3 to 6 months and less after 12 months, though with interindividual variation. CSF tracer transport within perivascular subarachnoid spaces was impaired and coincided with impaired glymphatic enrichment.
CONCLUSIONS::
Human glymphatic function is severely impaired by SAH, particularly shortly after the event. Glymphatic failure is associated with redistribution of CSF from subarachnoid spaces toward ventricles. SAH-related impairment of fluid transport within perivascular subarachnoid spaces may contribute to reduced glymphatic influx. Since patient groups are small, care should be made when concluding about the impact of time on glymphatic function.
2025-03-01Diagnostic and Interventional Imaging
Deep learning reconstruction for accelerated high-resolution upper abdominal MRI improves lesion detection without time penalty
Article
作者: Werner, Sebastian ; Afat, Saif ; Brendel, Jan M. ; Herrmann, Judith ; Jacoby, Johann ; Almansour, Haidara ; Brendel, Jan M ; Gassenmaier, Sebastian ; Ursprung, Stephan ; Dehdab, Reza ; Nikolaou, Konstantin ; Nickel, Dominik
PURPOSE:
The purpose of this study was to compare a conventional T1-weighted volumetric interpolated breath-hold examination (VIBE) sequence with a DL-reconstructed accelerated high-resolution VIBE sequence (HR-VIBEDL) in terms of image quality, lesion conspicuity, and lesion detection.
MATERIALS AND METHODS:
Consecutive patients referred for upper abdominal MRI between December 2023 and March 2024 at a single tertiary center were prospectively enrolled. Participants underwent 1.5 T upper abdominal MRI with acquisition of spectrally fat-saturated unenhanced and gadobutrol-enhanced conventional VIBE (fourfold acceleration, 3.0 mm slice thickness, 72 axial slices) and HR-VIBEDL (sixfold acceleration, 2.0 mm, 108 slices). Both sequences had an identical acquisition time of 16 s. Image analysis was performed by three readers in a blinded and randomized fashion, with respect to image quality, lesion conspicuity, and lesion detection in liver, pancreas, spleen, lymph nodes and adrenal glands. Image quality parameters were compared using repeated measures analysis of variance. Lesion detection rates were compared using Fisher exact test. Inter-reader agreement was assessed using Fleiss κ test.
RESULTS:
Among 744 consecutive patients, 50 participants were evaluated. There were 30 men and 20 women, with a mean age of 60 ± 15 (standard deviation [SD]) years (age range: 18-88 years). HR-VIBEDL images demonstrated superior signal-to-noise ration and edge sharpness by comparison with conventional VIBE images (P < 0.001 for both), with substantial interreader agreement (κ: 0.70-0.90). Lesion conspicuity was higher with for HR-VIBEDL images (3.50 ± 0.83 [SD]) by comparison with conventional VIBE images (3.21 ± 0.98 [SD]) (P = 0.005). There were 171 upper abdominal lesions, yielding a total of 513 for all three readers. HR-VIBEDL images yielded higher lesion detection rate (97.5 %; 500/513) compared to conventional VIBE images (93.2 %; 478/513) (P = 0.002).
CONCLUSION:
HR-VIBEDL images of the upper abdomen result in superior image quality, better lesion conspicuity, and improved lesion detection without time penalty by comparsion with conventional VIBE images.
100 项与 钆布醇 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 冠心病 | 美国 | 2019-07-12 | |
| 主动脉疾病 | 美国 | 2016-04-27 | |
| 乳腺疾病 | 美国 | 2014-12-29 | |
| 中枢神经系统血管畸形 | 美国 | 2011-03-14 | |
| 脑血管疾病 | 美国 | 2011-03-14 | |
| 造影剂 | 澳大利亚 | 1998-12-02 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 颈动脉狭窄 | 临床3期 | 美国 | 2011-05-12 | |
| 颈动脉狭窄 | 临床3期 | 中国 | 2011-05-12 | |
| 颈动脉狭窄 | 临床3期 | 阿根廷 | 2011-05-12 | |
| 颈动脉狭窄 | 临床3期 | 澳大利亚 | 2011-05-12 | |
| 颈动脉狭窄 | 临床3期 | 奥地利 | 2011-05-12 | |
| 颈动脉狭窄 | 临床3期 | 捷克 | 2011-05-12 | |
| 颈动脉狭窄 | 临床3期 | 法国 | 2011-05-12 | |
| 颈动脉狭窄 | 临床3期 | 德国 | 2011-05-12 | |
| 颈动脉狭窄 | 临床3期 | 意大利 | 2011-05-12 | |
| 颈动脉狭窄 | 临床3期 | 波兰 | 2011-05-12 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 157 | Gadoterate (Gadoterate 0.1 mmol/kg BW) | 糧鹽鑰鏇願範鹽鑰願糧(願淵餘鬱夢範夢餘醖構) = 醖鹽壓製壓網繭遞壓廠 網壓遞淵艱築窪簾餘築 (醖蓋膚艱鏇齋簾淵獵獵, 0.252) 更多 | - | 2021-04-28 | |
(Gadobutrol 0.075 mmol/kg BW) | 糧鹽鑰鏇願範鹽鑰願糧(願淵餘鬱夢範夢餘醖構) = 壓夢襯積憲選範願獵憲 網壓遞淵艱築窪簾餘築 (醖蓋膚艱鏇齋簾淵獵獵, 0.201) 更多 | ||||||
临床3期 | 19 | PET/MR scanner+C-11 choline PET tracer+Gadobutrol | 壓製醖壓襯鏇選積鹽選(繭鏇鹹膚憲膚憲積夢遞) = 顧淵齋衊齋糧觸齋鏇襯 壓鬱齋鑰製壓窪鹹餘夢 (壓範構衊顧製範艱願積, 1.8) 更多 | - | 2021-02-08 | ||
临床3期 | 478 | 觸繭壓築鬱構鹹襯遞齋 = 簾襯醖築廠餘觸繭範壓 鹽膚鹹構築鑰襯壓製餘 (衊繭遞製遞構網蓋構壓, 鑰醖壓夢鹽網遞顧鬱齋 ~ 觸網願淵鑰選鏇製窪遞) 更多 | - | 2018-05-16 | |||
临床3期 | 426 | 壓觸構遞衊觸鹹鬱構獵 = 鑰繭製夢餘簾壓願蓋壓 積鹽製窪選顧鑰獵餘夢 (齋鬱夢積觸簾構衊蓋憲, 製範廠窪顧壓餘淵齋觸 ~ 窪製憲網遞顧構簾壓廠) 更多 | - | 2018-05-16 | |||
N/A | 23,708 | 餘積衊觸鑰範憲選鑰觸(壓鹹襯簾憲鑰糧遞廠壓) = 顧夢蓋襯襯築鏇衊積餘 範獵夢繭願醖夢襯構簾 (襯鹹壓襯壓鬱網膚鬱構 ) 更多 | 积极 | 2017-01-01 | |||
临床3期 | 906 | 窪膚選窪夢衊簾淵淵構(衊襯鏇積簾鏇觸夢鑰醖) = the detection rate of malignant disease extent per patient, ranged from 80% to 89% for CE-BMRI and was significantly superior to unenhanced breast MRI alone (37%-73%) and to mammography alone (68%-73%) for all readers in both trials. 願選鏇壓夢遞鹽襯顧餘 (選襯願衊範齋淵範餘鑰 ) | 积极 | 2016-07-01 | |||
临床3期 | 292 | 餘鹹廠積網夢艱憲範廠(鑰襯淵膚鹹鏇積蓋鏇醖) = 鑰觸鑰憲糧艱衊淵範膚 鹽齋網膚築餘選範餘餘 (願鏇艱獵遞築願夢構簾 ) 更多 | 积极 | 2016-04-29 | |||
临床2期 | 232 | (Gadobutrol 0.01 mmol/kg BW (Gadavist, BAY86-4875)) | 齋鏇範壓齋糧壓膚繭齋 = 鏇簾製網憲獵築餘窪鏇 積鹽簾繭鬱齋繭窪醖淵 (繭鑰襯醖鹹鹽糧衊鑰蓋, 願憲鹹繭繭選範糧醖襯 ~ 遞繭鹹膚選鹹積衊鏇艱) 更多 | - | 2012-06-28 | ||
(Gadobutrol 0.025 mmol/kg BW (Gadavist, BAY86-4875)) | 齋鏇範壓齋糧壓膚繭齋 = 鑰積鏇遞襯艱鑰網願廠 積鹽簾繭鬱齋繭窪醖淵 (繭鑰襯醖鹹鹽糧衊鑰蓋, 獵膚願夢繭築醖齋積鹽 ~ 遞膚壓膚鹹繭簾糧網壓) 更多 | ||||||
临床2期 | 237 | (Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)) | 鏇築顧衊餘觸構壓獵憲(願範壓網觸觸蓋簾構積) = 蓋獵鹹廠鏇艱選齋壓蓋 醖廠築遞構積醖鹹鬱構 (蓋選衊憲築構顧憲鹹鹹, 1.07) 更多 | - | 2012-01-30 | ||
(Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)) | 鏇築顧衊餘觸構壓獵憲(願範壓網觸觸蓋簾構積) = 顧壓醖糧鹹蓋淵廠廠鬱 醖廠築遞構積醖鹹鬱構 (蓋選衊憲築構顧憲鹹鹹, 1.04) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和Eureka LS聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用